Isis Pharmaceuticals has initiated the development program of ISIS 301012 in patients with familial hypercholesterolemia (FH), a genetic disorder that causes extremely high cholesterol levels and results in the early onset of heart disease. ISIS 301012, a second-generation antisense drug, reduces levels of apoB-100, a protein critical to the synthesis and transport of the “bad” cholesterol involved in heart disease—low density lipoprotein cholesterol (LDL-C) and very low density lipo...